The strong results and reaffirmed guidance suggest continued momentum in Ligand's royalty portfolio. Traders should monitor upcoming catalysts from partner programs including Filspari, Ohtuvayre, and Tzield, which could provide additional upside.
LGND drugs
LGND drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $196.17entry
- T+1 · 9mo ago +1.09%α +1.54% · $198.31
- T+5 · 9mo ago +5.15%α +6.28% · $206.27
- T+20 · 8mo ago +3.84%α +10.24% · $203.70
- T+60 · 6mo ago +13.26%α +5.51% · $222.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ligand Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, driven by a 48% increase in royalty revenue. The company achieved GAAP net income of $124.5 million and core adjusted EPS of $8.13, exceeding prior guidance. Ligand is reaffirming its 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS.
Key Financial Metrics
Key Facts
- Full year 2025 revenue was $268.1 million, up from $167.1 million in 2024, driven by 48% growth in royalty revenue to $161.0 million
- Core adjusted EPS was $8.13 for 2025, exceeding initial guidance by approximately 30%
- GAAP net income was $124.5 million, a significant improvement from a $4.0 million net loss in 2024
- Company reaffirmed 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS
- Cash, cash equivalents, and short-term investments totaled $733.5 million as of December 31, 2025
Financial Impact
Revenue increased 60.4% year-over-year to $268.1 million, with core adjusted net income growing 52.2% to $165.1 million
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Royalties | $161.0M | +48.0% |
| Captisol | $40.2M | +30.1% |
| Contract revenue and income | $66.9M | +143.7% |
Risk Factors
- Future performance depends on partner drug development and commercialization success
- The $28.6 million gain from the Pelthos sale was a one-time item and not indicative of recurring performance
- Company faces risks related to partner program discontinuations and impairments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000886163-26-000003 |
| Document: lgnd-20260226.htm | 0000886163-26-000003 |
| Document: 0000886163-26-000003-index-headers.html | 0000886163-26-000003 |
| Document: 0000886163-26-000003-index.html | 0000886163-26-000003 |
| Document: 0000886163-26-000003.txt | 0000886163-26-000003 |
Track record
29 reports on LGND
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers